NovaEvum research news · Week of 2 November 2026
Tirzepatide, BPC-157 and Kisspeptin-10 Research
From the NovaEvum research desk · 8 papers from PubMed
This week we read eight new PubMed papers on peptides in the NovaEvum catalog: tirzepatide, BPC-157, TB-500, kisspeptin-10, SS-31, MOTS-c and retatrutide. They range from cell and rat studies of kisspeptin signalling and a mouse wound model using thymosin beta-4, to reviews of incretin agents in reproductive health, bone and fatty liver disease, an orthopaedic review of BPC-157, a computational MOTS-c screen and a Barth syndrome conference report covering SS-31.
- 2026 Dec
A cell and animal study of how ovarian sex steroids and kisspeptin-10 relate to PACAP gene expression in the hypothalamus. It used three hypothalamic cell lines alongside ovariectomized and ovary-intact female rats, and explored the two-way interaction between PACAP and kisspeptin signalling.
Regulation of PACAP gene expression by ovarian sex steroids and kisspeptin: Study using hypothalamic cell lines and an in vivo female rat model. Biochem Biophys Rep, 2026 Dec. PMID 42936012
- 2026 Dec
A narrative review of how GLP-1 receptor agonists, including tirzepatide, may interact with reproductive physiology. It covers hypothalamic-pituitary-ovarian signalling, oral contraceptive pharmacokinetics, fertility and pregnancy, and the authors note that human evidence on fertility and pregnancy safety remains limited.
GLP-1 Receptor Agonists and Reproductive Health: Implications for Contraception, Fertility, and Pregnancy. Endocrinol Metab Clin North Am, 2026 Dec. PMID 42907053
- 2026 Nov 02
A systematic review and meta-analysis of randomized, placebo-controlled human trials looking at GLP-1 receptor agonists and markers of bone metabolism, including bone mineral density and turnover markers. The authors found no eligible placebo-controlled trials of tirzepatide and call for dedicated skeletal studies.
The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents. Bone, 2026 Nov 02. PMID 42971377
- 2026 Oct 27
A narrative review for orthopaedic clinicians assessing the evidence on BPC-157, thymosin beta-4 and TB-500. It covers preclinical musculoskeletal studies, human data, product quality concerns, and regulatory and antidoping status, and the authors note that human evidence is minimal and largely limited to small-animal research.
Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg, 2026 Oct 27. PMID 42937313
- 2026 Oct 19
A conference report from the 2026 Barth Syndrome Foundation meeting. It summarizes sessions on cardiolipin biology, candidate therapeutic targets, gene and enzyme approaches, and natural history data, as well as the post-approval research program for elamipretide (SS-31), including its confirmatory trial.
Report from the 2026 Barth Syndrome Foundation International Scientific, Medical & Family Conference: Advances in Barth Syndrome Research, Therapy Development, and Clinical Care. J Dev Biol, 2026 Oct 19. PMID 42924728
- 2026 Oct 16
A mouse study comparing three recombinant thymosin isoforms from the American cockroach with thymosin beta-4, which served as a reference control, in a diabetic (ob/ob) excisional wound model. It used histology, CD31 staining and RNA sequencing of wound tissue to profile gene expression over time.
Comparative Transcriptomic Profiling of Diabetic Wound Responses to Recombinant Periplaneta americana Thymosin Isoforms in Male ob/ob Mice. Genes (Basel), 2026 Oct 16. PMID 42938412
- 2026
A computational study using bulk and single-cell transcriptomic data from a mouse model of chronic radiation proctitis to identify a fibrosis-associated macrophage subset. Molecular docking then nominated MOTS-c as a candidate binder, but MOTS-c was not tested in the laboratory.
Integrative transcriptomic and computational analysis associates Ms4a6c+ macrophages with fibrosis in radiation proctitis and computationally nominates MOTS-c as a candidate modulator. Front Immunol, 2026. PMID 42952740
- 2026
A narrative review of dual and triple incretin receptor agonists, including tirzepatide, survodutide and retatrutide, in the context of metabolic dysfunction-associated steatotic liver disease. It summarizes disease mechanisms and the published clinical trial programs for these multi-target agents.
From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease. Front Pharmacol, 2026. PMID 42947668
Each week NovaEvum reads the papers newly indexed on PubMed for the compounds we supply. Our summaries describe what each study examined and are not claims about any product, and paper titles are the authors’ own. Everything NovaEvum supplies is for laboratory research use only.
